

Javier Martinez-Trufero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2872534/publications.pdf>

Version: 2024-02-01

74
papers

2,343
citations

361045

20
h-index

223531

46
g-index

75
all docs

75
docs citations

75
times ranked

2920
citing authors

#	ARTICLE	IF	CITATIONS
1	Tongue Spindle Cell Rhabdomyosarcoma: A Rare Case Report and Literature Review. <i>Journal of Maxillofacial and Oral Surgery</i> , 2021, 20, 464-469.	0.6	2
2	Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 764-772.	1.2	13
3	A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. <i>Cancers</i> , 2021, 13, 792.	1.7	7
4	SEOM clinical guidelines for the treatment of head and neck cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 913-921.	1.2	40
5	Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. <i>Clinical and Translational Oncology</i> , 2021, 23, 1666-1677.	1.2	6
6	A DNA damage repair gene-associated signature predicts responses of patients with advanced soft tissue sarcoma to treatment with trabectedin. <i>Molecular Oncology</i> , 2021, 15, 3691-3705.	2.1	10
7	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS "GROUP). Part I. <i>Cancer Treatment Reviews</i> , 2021, 99, 102259.	3.4	6
8	Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS "GROUP). Part II. <i>Cancer Treatment Reviews</i> , 2021, 99, 102260.	3.4	7
9	Impact of an Oral Nutritional Protocol with Oligomeric Enteral Nutrition on the Quality of Life of Patients with Oncology Treatment-Related Diarrhea. <i>Nutrients</i> , 2021, 13, 84.	1.7	1
10	Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. , 2020, 8, e001561.		85
11	1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , 2020, 31, S975.	0.6	1
12	Clinical and Nutritional Effectiveness of a Nutritional Protocol with Oligomeric Enteral Nutrition in Patients with Oncology Treatment-Related Diarrhea. <i>Nutrients</i> , 2020, 12, 1534.	1.7	7
13	Oligomeric Enteral Nutrition in Undernutrition, due to Oncology Treatment-Related Diarrhea. Systematic Review and Proposal of An Algorithm of Action. <i>Nutrients</i> , 2019, 11, 1888.	1.7	18
14	Are Comorbidities Associated With Overall Survival in Patients With Oral Squamous Cell Carcinoma?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2019, 77, 1906-1914.	0.5	13
15	Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). <i>Oncologist</i> , 2019, 24, e338-e346.	1.9	44
16	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	1.9	22
17	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 134-144.	5.1	97
18	Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. <i>Targeted Oncology</i> , 2018, 13, 81-87.	1.7	8

#	ARTICLE	IF	CITATIONS
19	SEOM clinical guideline in nasopharynx cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 84-88.	1.2	26
20	Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 5239-5249.	3.2	21
21	Prognostic role of HMG proteins in a series of 301 advanced soft tissue sarcoma patients: A Spanish Group for Sarcoma Research Study (GEIS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11573-11573.	0.8	1
22	Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. <i>Oncotarget</i> , 2018, 9, 17576-17588.	0.8	1
23	New global prognosis score (GPSc) in resectable oral squamous cell carcinoma (OSCC): Joining up tumor and patient-related data.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18078-e18078.	0.8	0
24	Suboptimal regimens in sequential treatment (ST) with ICT (induction chemotherapy) followed by CCRT (concomitant chemotherapy) in "real life" patients with locally advanced pharyngo-laryngeal squamous-cell carcinoma (LAPLSCC) and prognosis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6075-6075.	0.8	0
25	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1). <i>Oral Oncology</i> , 2017, 70, 58-64.	0.8	20
26	Desmoid-Type Fibromatosis: Who, When, and How to Treat. <i>Current Treatment Options in Oncology</i> , 2017, 18, 29.	1.3	73
27	Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 473-480.	0.4	18
28	Malignant bone tumors (other than Ewing's sarcomas): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1113-1131.	1.1	30
29	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Oncology</i> , 2017, 28, 2994-2999.	0.6	45
30	PO-127: Melatonin oral gel for prevention oral mucositis head and neck cancer undergoing chemo/bio radiation (MUCOMEL). <i>Radiotherapy and Oncology</i> , 2017, 122, 61.	0.3	1
31	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). <i>British Journal of Cancer</i> , 2017, 117, 767-774.	2.9	17
32	Correlation between a new growth modulation index (GMI)-based Geistra score and efficacy outcomes in patients (PTS) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (T): A Spanish group for research on sarcomas (GEIS-38 study).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11070-11070.	0.8	3
33	Predictive role of FAS for trabectedin in second lines of advanced soft tissue sarcoma (ASTS): A Spanish group for research on sarcoma (GEIS) study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11071-11071.	0.8	2
34	Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2294-2302.	0.8	61
35	Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. <i>Oral Oncology</i> , 2016, 62, 54-59.	0.8	14
36	Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report. <i>Oncology Letters</i> , 2016, 12, 2936-2941.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. <i>Clinical Sarcoma Research</i> , 2016, 6, 10.	2.3	1
38	Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location. <i>Clinical and Translational Oncology</i> , 2016, 18, 1114-1122.	1.2	12
39	Phase II clinical trial evaluating the activity and tolerability of pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Studyâ€”NCT01692496.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11039-11039.	0.8	11
40	<i>CUL4A and ERCC1</i> genes predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11048-11048.	0.8	2
41	Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). <i>Annals of Surgical Oncology</i> , 2015, 22, 2948-2957.	0.7	47
42	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	1.9	30
43	A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. <i>Annals of Oncology</i> , 2014, 25, 216-225.	0.6	297
44	Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10594-10594.	0.8	2
45	Sorafenib in metastatic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 209-216.	1.6	96
46	In answer to: â€œComments to SEOM clinical guidelines for the treatment of thyroid cancerâ€”by Garcilaso Riesco-Eizaguirre et al. <i>Clinical and Translational Oncology</i> , 2012, 14, 711-712.	1.2	0
47	SEOM clinical guidelines for the treatment of thyroid cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 574-579.	1.2	14
48	Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2528-2533.	0.8	249
49	A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10072-10072.	0.8	5
50	<i>KIT, DOG1, PDGFR</i>, and <i>IGFR1</i> gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10047-10047.	0.8	1
51	Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10055-10055.	0.8	0
52	Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. <i>Anti-Cancer Drugs</i> , 2010, 21, 795-798.	0.7	14
53	Imatinib plus lowâ€”dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to highâ€”dose imatinib. <i>Cancer</i> , 2010, 116, 3692-3701.	2.0	33
54	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>British Journal of Cancer</i> , 2010, 102, 1687-1691.	2.9	52

#	ARTICLE	IF	CITATIONS
55	Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. <i>Annals of Oncology</i> , 2010, 21, 1552-1557.	0.6	64
56	Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study. <i>Journal of Clinical Oncology</i> , 2010, 28, 10070-10070.	0.8	0
57	Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 1893-1898.	0.8	64
58	Skull metastasis from rectal gastrointestinal stromal tumours. <i>Clinical and Translational Oncology</i> , 2009, 11, 625-627.	1.2	14
59	8520 Preliminary results of a pilot study with a modified induction docetaxel/cisplatin/5-FU (TPF) followed by concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC). <i>European Journal of Cancer, Supplement</i> , 2009, 7, 476-477.	2.2	0
60	Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous platinum-based treatment (PBT): Final results of Spanish Head and Neck Cancer Group (TTCC). <i>Journal of Clinical Oncology</i> , 2009, 27, 6047-6047.	0.8	3
61	A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results. <i>Journal of Clinical Oncology</i> , 2009, 27, 6039-6039.	0.8	1
62	Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 10570-10570.	0.8	0
63	Phase II study of capecitabine (X) as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous platinum-based treatment (PBT): An interim analysis. <i>Journal of Clinical Oncology</i> , 2007, 25, 6074-6074.	0.8	0
64	Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. <i>British Journal of Cancer</i> , 2006, 94, 1797-1802.	2.9	2
65	A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma. <i>Cancer</i> , 2005, 104, 1706-1712.	2.0	93
66	Serum Markers and Prognosis in Locally Advanced Breast Cancer. <i>Tumori</i> , 2005, 91, 522-530.	0.6	18
67	Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8636-8645.	0.8	408
68	Serum markers and prognosis in locally advanced breast cancer. <i>Tumori</i> , 2005, 91, 522-30.	0.6	7
69	Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 1498-1506.	2.0	18
70	Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias-A study of the Spanish Group for Research on Sarcomas (GEIS). <i>Journal of Surgical Oncology</i> , 2004, 88, 44-49.	0.8	7
71	Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2003, 14, 111-118.	0.7	2
72	Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. <i>European Journal of Cancer</i> , 2001, 37, 2385-2391.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2001, 12, 713-717.	0.7	20
74	Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. <i>Lung Cancer</i> , 2000, 30, 107-116.	0.9	12